Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors

Trial Profile

Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs DS 8201 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 07 Dec 2017 Updated results from two subgroups of patients with metastatic breast cancer ( n = 57) presented in a Daiichi Sankyo media release.
    • 07 Dec 2017 According to a Daiichi Sankyo media release, updated safety and efficacy data from two subgroups of patients with metastatic breast cancer (n = 57) were presented at the 2017 San Antonio Breast Cancer Symposium.
    • 14 Nov 2017 According to Daiichi Sankyo media release,data will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top